The specter of generic competition has long loomed above copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the future of similar medicinal stakes. While early years saw substantial gains, the exclusivity end has opened the way for cheaper alternatives, possibly diminishing earnings and posing a real risk for investors pursuing sec